The complex capsule of Rui Lage urea solid preparation and metformin solid preparation is housed
Technical field the present invention relates to a kind of oral hard capsule, is filled with the complex capsule of Rui Lage urea solid preparation and metformin solid preparation in particularly a kind of capsule.
Background technology compound recipe Rui Lage urea metformin hydrochloride tablet is the product of Novo Nordisk Co.,Ltd, and its commodity are called PrandiMet, are used for the treatment of type 2 diabetes mellitus, comprises two kinds of specifications of Rui Lage urea/metformin hydrochloride 1mg/500mg and 2mg/500mg.This product be proved to be can reduce can not adopt the sharp urea of MAG and (or) metformin controls the blood glucose of the type 2 diabetes mellitus adult patient of hyperglycemia well.Drugs approved by FDA PrandiMet listing is based on Rui Lage urea/metformin hydrochloride 1mg/500mg, the Rui Lage urea of 2mg/500mg and corresponding dosage and metformin hydrochloride single medicine preparation share the bioequivalence data that are close, clinical research proves, PrandiMet can reduce HbA1 c concentration safely and effectively, the preparation that this product provides two medicines conveniently to take medicine in 1, auspicious glug urea stimulates pancreatic secretion insulin after the meal, thereby reduce by 2 hours after the meal blood glucose (PPG), metformin reduces hepatogenous blood glucose amount, thereby reduce fasting glucose (FPG), improve the natural reaction of human body insulin.
There is the possibility that contacts in two kinds of active component of metformin and Rui Lage urea in the above-mentioned dosage form.And the various active composition is all in same minimum preparation unit.
If active component contacts with each other, have following shortcoming: 1, because multicomponent mixing homogeneity degree influences, each composition is difficult to accurately quantitatively; When 2, product detects,, influence the qualitative and quantitative analysis result because the phase mutual interference is difficult for measuring each component content; 3, during long preservation, change because chemical compatibility may take place between each composition, be easy to generate by-product, reduce effect or increase side effect, product stability is not ideal enough.Because above-mentioned defective exists, there are many advantages although contain the existing compound recipe dosage form of Rui Lage urea, but still may cause harmful effect product quality and human body health.
Though can come the quality of strict control medicine in the pharmaceuticals industry by the GMP standard, find simple production technology to guarantee that the quality of medicine remains one of direction of drug research and development, also meets the aim of medicine GMP.
Summary of the invention
The invention provides a kind of complex capsule that metformin solid preparation and Rui Lage urea solid preparation are housed, do not contact mutually between the various active component in the capsule, thereby obtain stability complex capsule better, easy to process.
Complex capsule of the present invention is made up of the solid preparation in first capsule and first capsule, and the complex capsule that first capsule comprises is characterized in that, described solid preparation is the tablet or second capsule.
Preferred complex capsule of the present invention, wherein tablet is a coating.
Complex capsule of the present invention, wherein the coating of tablet is a different colours, described tablet is the identical cylinder of shape.
Complex capsule, it is characterized in that described first capsule is No. 0 or No. 1 capsule, and first capsularly goes up utricule and following utricule is colourless.
Complex capsule of the present invention, wherein first capsule is No. 0 or No. 1 capsule, thus for the first capsular compliance that increases the patient attractive in appearance, the first capsular utricule of going up is colourless with following utricule.
In order to be fit to that mechanization is produced and to be convenient to be identified, but various tablets or the identical color difference of the second capsular shape in first capsule.
Particularly in order to adapt to the capsule filling machine that goes on the market and use, the shape of described various tablets is made into column type.Automatic capsule filling machine (KF-S50) such as Korea S INNOTECH SYSTEMS LTD. company.
Also in order to adapt to the slice, thin piece of different content active component, also can select the capsule of other models simultaneously.
The utilization of technique scheme, the present invention compared with prior art have following advantage:
1. because the active component in first capsule is not contacted each other; therefore chemistry 5 changes can not take place between each composition and produce by-product; especially for having the amido link of replacement that good protection is arranged on the ester bond of metformin and the N, the stability of product is improved.
2. owing to adopted the design of column type slice, thin piece and different colours, and the application of transparent softgel shell, make product of the present invention be fit to very much suitability for industrialized production, strengthened patient's compliance.
3. because the present invention adopts is active component film-making respectively, on the check of medicine and quality control, be more prone to.
Description of drawings
Accompanying drawing 1 is the axonometric chart of the complex capsule of embodiments of the invention 1.Wherein, 1, capsule body down; 2, go up capsule body; 3, first diformin tablet; 4, Rui Lage urea sheet; 5, second diformin tablet.
Accompanying drawing 2 is the exploded perspective view of the complex capsule of embodiment 1.1, following capsule body; 2, go up capsule body; 3, diformin tablet; 4, Rui Lage urea sheet; 5, amlodipine sheet.
Accompanying drawing 3 is the A-A cutaway view of the complex capsule of embodiment 1.Wherein, 1, capsule body down; 2, go up capsule body; 3, first diformin tablet; 4, Rui Lage urea sheet; 5, second diformin tablet.
Accompanying drawing 4 is the cutaway view of embodiments of the invention 2.Wherein, 1, capsule body down; 2, go up capsule body; 3, diformin tablet; 4, Rui Lage urea sheet.
The specific embodiment
Below in conjunction with drawings and Examples the present invention is further described:
Embodiment 1: shown in accompanying drawing 1-3, and the complex capsule of one first diformin tablet of filling, a Rui Lage urea sheet and one second diformin tablet in the seed capsules.The first capsule specification is No. 0.First capsule housing is by capsule body 1 and last capsule body 2 suits constitute down, the slice of cylinder of above-mentioned 3 different colours coatings is housed, is respectively first diformin tablet (containing metformin 250mg), Rui Lage urea (containing Rui Lage urea 1mg) and second diformin tablet (containing metformin 250mg).
First metformin is that yellow stomach dissolution type film-coat, Rui Lage urea sheet are that red film-coat, second metformin is black stomach dissolution type film-coat or all adopts identical color.
Embodiment 2: shown in accompanying drawing 4, and the complex capsule of a diformin tablet of filling and a Rui Lage urea sheet in the seed capsules.The first capsule specification is No. 0.First capsule housing is made of with last capsule body 2 suits following capsule body 1, and the slice of cylinder of above-mentioned 2 different colours coatings is housed, and is respectively diformin tablet (containing metformin 250mg), Rui Lage urea sheet (Rui Lage urea 1mg).Auspicious glug urea sheet is that yellow stomach dissolution type film-coat, diformin tablet are red film-coat.
The steadiness of complex capsule of the present invention is described below in conjunction with the test example
Test example 1 is carried out hot test (60 ℃), high wet test (RH75%), exposure experiments to light (3000LX) respectively with embodiment 1,2 prepared complex capsules and is carried out test in 10 days, the results are shown in Table 1-3:
Table 1, hot test
|
|
Embodiment 1 |
Embodiment 2 |
0 day content |
Metformin (%) |
??99.56 |
??99.44 |
|
Auspicious glug urea (%) |
??99.79 |
??100.1 |
0 day related substance |
Metformin (%) |
??0.31 |
??0.22 |
5 days content |
Metformin (%) |
??99.43 |
??99.47 |
|
Auspicious glug urea (%) |
??99.38 |
??100.1 |
5 related substances |
Metformin (%) |
??0.28 |
??0.18 |
10 days content |
Metformin (%) |
??99.11 |
??99.23 |
|
Auspicious glug urea (%) |
??99.33 |
??100.2 |
10 days related substances |
Metformin (%) |
??0.27 |
??0.17 |
Annotate: content is sign content in the table
Table 2, high wet test
|
|
Embodiment 1 |
Embodiment 2 |
0 day content |
Metformin (%) |
??99.56 |
??99.44 |
|
Auspicious glug urea (%) |
??99.79 |
??100.1 |
0 day related substance |
Metformin (%) |
??0.31 |
??0.22 |
5 days content |
Metformin (%) |
??99.46 |
??99.48 |
|
Auspicious glug urea (%) |
??99.42 |
??99.32 |
5 related substances |
Metformin (%) |
??0.24 |
??0.30 |
10 days content |
Metformin (%) |
??99.31 |
??99.76 |
|
Auspicious glug urea (%) |
??99.43 |
??99.63 |
10 days related substances |
Metformin (%) |
??0.32 |
??0.35 |
Annotate: content is sign content in the table
Table 3, exposure experiments to light
|
|
Embodiment 1 |
Embodiment 2 |
0 day content |
Metformin (%) |
??99.23 |
??99.77 |
|
Auspicious glug urea (%) |
??99.76 |
??99.79 |
0 day related substance |
Metformin (%) |
??0.38 |
??0.37 |
5 days content |
Metformin (%) |
??99.44 |
??99.69 |
|
Auspicious glug urea (%) |
??99.35 |
??99.39 |
5 related substances |
Metformin (%) |
??0.32 |
??0.38 |
10 days content |
Metformin (%) |
??99.11 |
??99.26 |
|
Auspicious glug urea (%) |
??99.33 |
??99.43 |
10 days related substances |
Metformin (%) |
??0.37 |
??0.32 |
Annotate: content is sign content in the table
Stability test is the result show, it is less relatively that embodiments of the invention obtain the generation of product related substance, and content does not reduce.Owing to be to measure respectively, detection method is easy, needn't consider compound medicine between the phase mutual interference.